<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>药事纵横 | wechat-feeds</title><link>http://MzI5ODI5NDE2OA.favicon.privacyhide.com/favicon.ico</link><description>药事纵横是一个由多位制药精英联合创办的媒体平台，旨在分享与传递药品研发、生产和注册中所涉及的技术、经验和情报，欢迎关注和投稿！投稿请发442015666@qq.com</description><managingEditor> (hellodword)</managingEditor><pubDate>Wed, 17 Mar 2021 09:52:59 +0800</pubDate><image><url>http://MzI5ODI5NDE2OA.favicon.privacyhide.com/favicon.ico</url><title>药事纵横 | wechat-feeds</title><link>http://MzI5ODI5NDE2OA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>固体分散体技术在创新药制剂开发中的应用</title><link>https://mp.weixin.qq.com/s/5se4RvuJdiwb9IM9XzR_mg</link><description></description><content:encoded><![CDATA[固体分散体技术在创新药制剂开发中的应用]]></content:encoded><pubDate>Tue, 16 Mar 2021 20:19:53 +0800</pubDate></item><item><title>免费领取罕见病研发白皮书，了解Pre-IND的六大注意事项</title><link>https://mp.weixin.qq.com/s/9eLBpjWKHJQa-gAmqJbv7A</link><description></description><content:encoded><![CDATA[免费领取罕见病研发白皮书，了解Pre-IND的六大注意事项]]></content:encoded><pubDate>Tue, 16 Mar 2021 20:19:53 +0800</pubDate></item><item><title>双特异性抗体那些事儿</title><link>https://mp.weixin.qq.com/s/SvvO2JVwX_oe39luixx2Dg</link><description></description><content:encoded><![CDATA[双特异性抗体那些事儿]]></content:encoded><pubDate>Tue, 16 Mar 2021 20:19:53 +0800</pubDate></item><item><title>蛋白降解靶向嵌合体（PROTAC）在小分子药物研发中的机遇与挑战</title><link>https://mp.weixin.qq.com/s/OJov6Ilxna8ygRwGqyAXxg</link><description></description><content:encoded><![CDATA[蛋白降解靶向嵌合体（PROTAC）在小分子药物研发中的机遇与挑战]]></content:encoded><pubDate>Mon, 15 Mar 2021 20:18:39 +0800</pubDate></item><item><title>2021药品研发分析和QC实验室合规并如何从困惑走向卓越</title><link>https://mp.weixin.qq.com/s/eKGMA1MRoJ4Y2Mq_pSEOyg</link><description></description><content:encoded><![CDATA[2021药品研发分析和QC实验室合规并如何从困惑走向卓越]]></content:encoded><pubDate>Mon, 15 Mar 2021 20:18:39 +0800</pubDate></item><item><title>对一期临床前制剂研发的建议</title><link>https://mp.weixin.qq.com/s/kduU9b7jbUlFhJS7JDln_w</link><description></description><content:encoded><![CDATA[对一期临床前制剂研发的建议]]></content:encoded><pubDate>Mon, 15 Mar 2021 20:18:39 +0800</pubDate></item><item><title>如何让你开发的方法更利于转移</title><link>https://mp.weixin.qq.com/s/ZmAG2iLZDS4sEJWR29UgOw</link><description></description><content:encoded><![CDATA[如何让你开发的方法更利于转移]]></content:encoded><pubDate>Mon, 15 Mar 2021 07:30:47 +0800</pubDate></item><item><title>【最后五天】药品注册现场核查及M4注册申报文件撰写与递交</title><link>https://mp.weixin.qq.com/s/yFj-K_iZYwjmgsa2TnBuFQ</link><description></description><content:encoded><![CDATA[【最后五天】药品注册现场核查及M4注册申报文件撰写与递交]]></content:encoded><pubDate>Mon, 15 Mar 2021 07:30:47 +0800</pubDate></item><item><title>由药片出现黑点问题引发的思考</title><link>https://mp.weixin.qq.com/s/6CXX1x8PSsDgVA78siWY9Q</link><description></description><content:encoded><![CDATA[由药片出现黑点问题引发的思考]]></content:encoded><pubDate>Mon, 15 Mar 2021 07:30:47 +0800</pubDate></item><item><title>西地那非（伟哥）：失败的临床试验中发现的意外惊喜</title><link>https://mp.weixin.qq.com/s/UYQ-mFvKyDlGfhbrO_9afg</link><description></description><content:encoded><![CDATA[西地那非（伟哥）：失败的临床试验中发现的意外惊喜]]></content:encoded><pubDate>Fri, 12 Mar 2021 09:27:14 +0800</pubDate></item><item><title>清单管理——简化研发工作</title><link>https://mp.weixin.qq.com/s/NEaGF6XKP3rXeiJXQ-19lg</link><description></description><content:encoded><![CDATA[清单管理——简化研发工作]]></content:encoded><pubDate>Fri, 12 Mar 2021 09:27:14 +0800</pubDate></item><item><title>药事纵横广告投放须知</title><link>https://mp.weixin.qq.com/s/PdmYJgo_E8ktOQPEoIRUaA</link><description></description><content:encoded><![CDATA[药事纵横广告投放须知]]></content:encoded><pubDate>Fri, 12 Mar 2021 09:27:14 +0800</pubDate></item><item><title>药物研发中的盐型筛选</title><link>https://mp.weixin.qq.com/s/WdvZUdkt5wxNf9RngSgGfg</link><description></description><content:encoded><![CDATA[药物研发中的盐型筛选]]></content:encoded><pubDate>Wed, 10 Mar 2021 18:12:07 +0800</pubDate></item><item><title>复杂体系中活性成分的鉴别及验证策略</title><link>https://mp.weixin.qq.com/s/oxiHSNgmQkQJ1SUWPPr0sw</link><description></description><content:encoded><![CDATA[复杂体系中活性成分的鉴别及验证策略]]></content:encoded><pubDate>Wed, 10 Mar 2021 18:12:07 +0800</pubDate></item><item><title>稿费已经上调，期待广大读者朋友投稿</title><link>https://mp.weixin.qq.com/s/2Z8WyWGBxvUANUyclnMkvg</link><description></description><content:encoded><![CDATA[稿费已经上调，期待广大读者朋友投稿]]></content:encoded><pubDate>Wed, 10 Mar 2021 18:12:07 +0800</pubDate></item><item><title>难溶药物——难溶性强弱判定</title><link>https://mp.weixin.qq.com/s/Fu7G5hxNUHiPBEHaL-V-PQ</link><description></description><content:encoded><![CDATA[难溶药物——难溶性强弱判定]]></content:encoded><pubDate>Tue, 09 Mar 2021 16:25:15 +0800</pubDate></item><item><title>中国药科大学：2021药品企业QA管理能力提升研修班</title><link>https://mp.weixin.qq.com/s/WTI_YFpJBWuC3Haeka6c8Q</link><description></description><content:encoded><![CDATA[中国药科大学：2021药品企业QA管理能力提升研修班]]></content:encoded><pubDate>Tue, 09 Mar 2021 16:25:15 +0800</pubDate></item><item><title>关于乙肝你了解多少？</title><link>https://mp.weixin.qq.com/s/F7Rco0c9WotFPcTcsVfpVA</link><description></description><content:encoded><![CDATA[关于乙肝你了解多少？]]></content:encoded><pubDate>Tue, 09 Mar 2021 16:25:15 +0800</pubDate></item><item><title>【原创】药用辅料理化性质的差异性对药品质量特性的影响</title><link>https://mp.weixin.qq.com/s/F7zkER4Q_4417Zf0I_WSrA</link><description></description><content:encoded><![CDATA[【原创】药用辅料理化性质的差异性对药品质量特性的影响]]></content:encoded><pubDate>Mon, 08 Mar 2021 20:55:20 +0800</pubDate></item><item><title>【倒计时10天】药品注册现场核查及M4注册申报文件撰写与递交</title><link>https://mp.weixin.qq.com/s/6L41WnRqRclhixXZLigreQ</link><description></description><content:encoded><![CDATA[【倒计时10天】药品注册现场核查及M4注册申报文件撰写与递交]]></content:encoded><pubDate>Mon, 08 Mar 2021 20:55:20 +0800</pubDate></item></channel></rss>